高流量鼻氧与无创通气治疗急性呼吸衰竭:RENOVATE随机临床试验
RENOVATE非劣效随机试验在巴西33家医院纳入1800例急性呼吸衰竭成人,随机接受高流量鼻氧(n=883)或无创通气(n=883),主要终点为7天内气管插管或死亡。高流量鼻氧组主要终点发生率为39%(344/883),无创通气组为38%(336/883)。在非免疫抑制低氧血症、急性心源性肺水肿、COVID-19低氧血症和COPD急性加重伴呼吸性酸中毒4组中达到预设非劣效标准(非劣效后验概率≥0.992),但免疫抑制低氧血症组因无效提前停止入组(非劣效后验概率0.989)。事后不采用动态借用的分析在COPD、免疫抑制和急性心源性肺水肿患者中显示定性不同的结果,作者建议对这些人群进一步研究。
要点
- 总体7天内气管插管或死亡:高流量鼻氧组39%(344/883) vs 无创通气组38%(336/883)。
- 非免疫抑制低氧血症组:高流量鼻氧32.5%(81/249) vs 无创通气33.1%(78/236),OR 1.02(95%CrI 0.81-1.26),非劣效后验概率0.999。
- 急性心源性肺水肿组:高流量鼻氧10.3%(14/136) vs 无创通气21.3%(29/136),OR 0.97(95%CrI 0.73-1.23),非劣效后验概率0.997。
- COVID-19低氧血症组:高流量鼻氧51.3%(223/435) vs 无创通气47.0%(210/447),OR 1.13(95%CrI 0.94-1.38),非劣效后验概率0.997。
- COPD急性加重伴呼吸性酸中毒组:高流量鼻氧28.6%(10/35) vs 无创通气26.2%(11/42),OR 1.05(95%CrI 0.79-1.36),非劣效后验概率0.992;免疫抑制低氧血症组因无效提前停止入组,OR 1.07(95%CrI 0.81-1.39),非劣效后验概率0.989。
适用人群与场景
- 住院成人(年龄≥18岁)急性呼吸衰竭患者,分为5组:非免疫抑制伴低氧血症、免疫抑制伴低氧血症、COPD急性加重伴呼吸性酸中毒、急性心源性肺水肿(ACPE)、低氧血症COVID-19(2023年6月26日新增为独立组)。
- 研究在巴西33家医院进行,纳入时间为2019年11月至2023年11月,最终随访至2024年4月26日。
诊断标准与关键阈值
- 非劣效性定义为:比值比(OR)小于1.55的后验概率≥0.992。
- 主要终点为7天内气管插管或死亡,采用贝叶斯分层模型并在患者组间进行动态借用。
研究设计与关键结果
- 研究类型:非劣效、随机临床试验;样本量1800例(高流量鼻氧组n=883,无创通气组n=883),1766例完成研究;平均年龄64岁(SD 17),女性707例(40%)。
- 主要终点7天内气管插管或死亡:高流量鼻氧组39%(344/883) vs 无创通气组38%(336/883)。
- 非免疫抑制伴低氧血症组:高流量鼻氧组32.5%(81/249) vs 无创通气组33.1%(78/236),OR 1.02(95%CrI 0.81-1.26),非劣效后验概率0.999。
- 免疫抑制伴低氧血症组:高流量鼻氧组57.1%(16/28) vs 无创通气组36.4%(8/22),OR 1.07(95%CrI 0.81-1.39),非劣效后验概率0.989,因无效提前停止入组。
- 急性心源性肺水肿组:高流量鼻氧组10.3%(14/136) vs 无创通气组21.3%(29/136),OR 0.97(95%CrI 0.73-1.23),非劣效后验概率0.997。
- 低氧血症COVID-19组:高流量鼻氧组51.3%(223/435) vs 无创通气组47.0%(210/447),OR 1.13(95%CrI 0.94-1.38),非劣效后验概率0.997。
- COPD急性加重伴呼吸性酸中毒组:高流量鼻氧组28.6%(10/35) vs 无创通气组26.2%(11/42),OR 1.05(95%CrI 0.79-1.36),非劣效后验概率0.992。
- 严重不良事件发生率:高流量鼻氧组9.4% vs 无创通气组9.9%。
证据类型、等级与局限
- 证据类型:非劣效、随机临床试验(RENOVATE)。
- 局限:原文报告部分患者组样本量小,且结果对分析模型的选择敏感,提示需要在COPD、免疫抑制和急性心源性肺水肿患者中进一步研究。
对床旁实践的改变
- 在非免疫抑制伴低氧血症、急性心源性肺水肿、低氧血症COVID-19和COPD急性加重伴呼吸性酸中毒患者中,高流量鼻氧达到预设非劣效标准;但作者指出部分组样本量小且结果对分析模型敏感,认为需要在COPD、免疫抑制和急性心源性肺水肿患者中进一步研究。
指南或共识出处
- RENOVATE随机临床试验(ClinicalTrials.gov Identifier: NCT03643939),发表于JAMA。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: High-flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) are commonly used respiratory support therapies for patients with acute respiratory failure (ARF).
OBJECTIVE: To assess whether HFNO is noninferior to NIV on the rates of endotracheal intubation or death at 7 days in 5 patient groups with ARF.
DESIGN, SETTING, AND PARTICIPANTS: This noninferiority, randomized clinical trial enrolled hospitalized adults (aged ≥18 years; classified as 5 patient groups with ARF: nonimmunocompromised with hypoxemia, immunocompromised with hypoxemia, chronic obstructive pulmonary disease [COPD] exacerbation with respiratory acidosis, acute cardiogenic pulmonary edema [ACPE], or hypoxemic COVID-19, which was added as a separate group on June 26, 2023) at 33 hospitals in Brazil between November 2019 and November 2023 (final follow-up: April 26, 2024).
INTERVENTIONS: High-flow nasal oxygen (n = 883) or NIV (n = 883).
MAIN OUTCOMES AND MEASURES: The primary outcome was endotracheal intubation or death within 7 days assessed using a bayesian hierarchical model with dynamic borrowing across patient groups. Noninferiority was defined by a posterior probability of 0.992 or greater for an odds ratio (OR) less than 1.55.
RESULTS: Among 1800 patients, 1766 completed the study (mean age, 64 [SD, 17] years; 707 [40%] were women). The primary outcome of endotracheal intubation or death at 7 days occurred in 39% (344/883) in the HFNO group vs 38% (336/883) in the NIV group. In the immunocompromised with hypoxemia patient group, the primary outcome occurred in 57.1% (16/28) in the HFNO group vs 36.4% (8/22) in the NIV group; enrollment was stopped for futility (final OR, 1.07; 95% credible interval [CrI], 0.81-1.39; noninferiority posterior probability [NPP], 0.989). In the nonimmunocompromised with hypoxemia group, the primary outcome occurred in 32.5% (81/249) in the HFNO group vs 33.1% (78/236) in the NIV group (OR, 1.02 [95% CrI, 0.81-1.26]; NPP, 0.999). In the ACPE group, the primary outcome occurred in 10.3% (14/136) in the HFNO group vs 21.3% (29/136) in the NIV group (OR, 0.97 [95% CrI, 0.73-1.23]; NPP, 0.997). In the hypoxemic COVID-19 group, the primary outcome occurred in 51.3% (223/435) in the HFNO group vs 47.0% (210/447) in the NIV group (OR, 1.13 [95% CrI, 0.94-1.38]; NPP, 0.997). In the COPD exacerbation with respiratory acidosis group, the primary outcome occurred in 28.6% (10/35) in the HFNO group vs 26.2% (11/42) in the NIV group (OR, 1.05 [95% CrI, 0.79-1.36]; NPP, 0.992). However, a post hoc analysis without dynamic borrowing across the 5 ARF patient groups revealed some qualitatively different results in patients with COPD, immunocompromised patients, and patients with ACPE. The incidence of serious adverse events was similar (9.4% of patients in HFNO group vs 9.9% in NIV group).
CONCLUSIONS AND RELEVANCE: Compared with NIV, HFNO met prespecified criteria for noninferiority for the primary outcome of endotracheal intubation or death within 7 days in 4 of the 5 patient groups with ARF. However, the small sample sizes in some patient groups and the sensitivity of the findings to the choice of analysis model suggests the need for further study in patients with COPD, immunocompromised patients, and patients with ACPE.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03643939.
参考来源
- Maia IS, Kawano-Dourado L, Tramujas L, et al. High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial. JAMA. 2025. PMID: 39657981. doi:10.1001/jama.2024.26244
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。